MURRAY, Utah, Nov. 12, 2026 (GLOBE NEWSWIRE) — FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), parent company of FinWise Bank (the “Bank”), today announced that its Board of Directors has authorized an additional 600,000 shares of the Company’s common stock that may be repurchased pursuant to its repurchase program. The program was originally approved by the Board on May 19, 2026, to purchase up to 685,000 shares, or approximately 5% of issued and outstanding shares. As of November 11, 2026, approximately 415,000 shares remained available under the existing authorization. Since the program’s inception, the Company has repurchased 270,000 shares of the Company’s common stock for an aggregate purchase price of $3.7 million. The 600,000 additional shares authorized for the program represent approximately 4.4% of the Company’s outstanding shares of common stock. The repurchases will be made at the Company’s discretion with an expiration of May 31, 2028.

“The Board’s authorization of additional shares for our share repurchase program reflects our strong capital position and confidence in the long-term trajectory of the business,” said Jim Noone, CEO of FinWise Bancorp. “We ended the third quarter with a Bank Leverage Ratio of 18.1%, more than double the well-capitalized threshold, and tangible book value of $15.14 per share.”

Under the repurchase program, the Company may, from time to time and on or before the program’s expiration date, repurchase shares of its outstanding common stock in the open market, in privately negotiated transactions, or otherwise, subject to applicable laws and regulations. The extent to which the Company repurchases its shares, and the means and timing of such repurchases, will depend upon a variety of factors, including market conditions, regulatory requirements, availability of funds, and other relevant considerations, as determined by the Company. The repurchase program does not obligate the Company to purchase any particular number of shares. The Company may, in its discretion, begin, suspend, limit or terminate repurchases at any time prior to the program’s expiration, without any prior notice. Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. The Company expects to fund repurchases under the program with its available cash balances.

About FinWise

FinWise provides Banking and Payments solutions to fintech brands. Its existing Strategic Program Lending business, conducted through scalable API-driven infrastructure, powers deposit, lending and payments programs for leading fintech brands.

As part of Strategic Program Lending, FinWise also provides a Credit Enhanced Balance Sheet Program, which addresses the challenges that lending and card programs face diversifying their funding sources and managing capital efficiency.

In addition, FinWise manages other Lending programs such as SBA 7(a), Owner Occupied Commercial Real Estate, and Leasing, which provide flexibility for disciplined balance sheet growth. The Company is also expanding and diversifying its business model by incorporating Payments (MoneyRails™) and BIN Sponsorship offerings.

Through its compliance oversight and risk management-first culture, the Company is well positioned to guide fintechs through a rigorous process to facilitate regulatory compliance.

https://www.finwise.bank/

Contacts

investors@finwisebank.com
media@finwisebank.com

— Following positive NEXICART-2 clinical update, commercial launch preparation continues with commercial site activation activities, strengthened team, and provider and payer engagement —

— Interim NEXICART-2 clinical trial results selected for oral presentation at ASH 2026 —

LOS ANGELES, Nov. 12, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“Immix”, the “Company”, “we” or “us”), a global leader in AL amyloidosis, today reported an update on corporate progress and financial results for the quarter ended September 30, 2026.

Recent NXC-201 Progress

– Positive clinical data: 89% complete response rate was reported across all 45 NEXICART-2 patients, with MRD-negativity indicating potential to reach up to 98% complete response rate in the future.
   
– Immix continues to advance its AL Amyloidosis launch readiness activities across commercial site activation, provider and payer engagement, manufacturing activities, and healthcare professional education.
   

Immix plans for its BLA submission in mid-2027, and NEXICART-3 front line trial initiation in the first half of 2027.

Interim NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at 68th American Society of Hematology (ASH) Annual Meeting

On Monday, December 14, 2026, NXC-201 NEXICART-2 interim clinical data will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.  

Commercial Launch Preparation Continues with Strengthened Team

Immix has appointed David He, MD, PhD as Senior Vice President, Head of Technical Operations. Dr. He has contributed in a senior role to two approved BCMA CAR-Ts, CARVYKTI® and FUCASO®. Dr. He will lead chemistry, manufacturing, and controls at Immix, further accelerating the Company’s planned path to commercialization. Prior to Immix, Dr. He served as the Chief Technology Officer from pre-BLA to commercial-stage at IASO Biotherapeutics and as the Vice President, Technical Operations at Legend Biotech, as well as in a senior chemistry, manufacturing, and controls positions at Boehringer Ingelheim, and other senior roles.

Immix has appointed Karin McIntosh as Senior Vice President, Head of Regulatory Affairs. Karin has contributed to multiple FDA drug programs, including JANUVIA® (FDA+EMA), EMFLAZA® (FDA), ELZONRIS® (FDA+EMA), and most recently, the approval of TREGZI® (FDA, 2026). Karin will lead regulatory affairs at Immix in the United States and globally. Prior to Immix, Karin was Vice President, Head of Regulatory Affairs at Orca Bio and held senior regulatory positions at Stemline Therapeutics, PTC Therapeutics, Merck, and Pfizer.

Additionally, Immix has appointed additional key team members across its Commercial, Regulatory, Quality, Medical Affairs teams, and as Medical Science Liaisons.

Upcoming Events

– In addition to NEXICART-2 interim clinical data being presented at ASH on Monday December 14, 2026, the Company will also present at the 45th Annual J.P. Morgan Healthcare Conference being held in San Francisco from January 11 – 14, 2027.
   

Financial Results for the Third Quarter Ended September 30, 2026

– Immix reported $340.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which is expected to provide operating runway into mid-2028.
   
– Immix reported $15.9 million in operating expenses for the third quarter ended September 30, 2026.
   

About AL Amyloidosis
Amyloid light-chain (AL) amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead continuously produces toxic light chains that build up in organs including the heart, kidney, and liver, causing organ failure and death.

AL amyloidosis is the most common form of amyloidosis according to the National Institutes of Health. The number of patients in the U.S. with relapsed/refractory AL Amyloidosis is estimated to be growing at 12% per year according to Staron, et al Blood Cancer Journal, to approximately 30,506 patients in 2026.

The Amyloidosis market was $6.2 billion in 2025, and is expected to reach $6.6 billion in 2026, according to Grand View Research.

About NXC-201
NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.

About Immix Biopharma, Inc.
Immix Biopharma, Inc. (Nasdaq: IMMX) is a global leader in AL amyloidosis. AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Forward-Looking Statements
This press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, statements relating to the potential of NXC-201 to reach up to a 98% complete response rate, the Company’s commercial launch readiness activities, the planned timing of the Company’s BLA submission and the initiation of the NEXICART-3 front line trial, the presentation of NEXICART-2 interim clinical data at ASH, the Company presenting at the 45th Annual J.P. Morgan Healthcare Conference, the contributions to be made by Dr. He, Karin McIntosh and other new team members, including accelerating the planned path to commercialization, cash, cash equivalents, and marketable securities expected to provide operating runway into mid-2028 and expected growth of the AL amyloidosis market. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the estimates for the number of patients in the U.S. with relapsed/refractory AL Amyloidosis and the market size reaching not being accurate; (ii) the risk that Breakthrough Therapy designation will not expedite the development of NXC-201: (iii) the risk that further data from the ongoing Phase 1/2 clinical trials for NXC-201 will not be favorably consistent with the data readouts to date, including the risk that MRD-negativity will not translate into higher complete response rates; (iv) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (v) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (vi) the risk that the Company may not submit its BLA in mid-2027 or initiate the NEXICART-3 front line trial in the first half of 2027, or at all, and that any BLA submitted may not be accepted or approved by the FDA on a timely basis or at all; (vii) the risk that the Company’s commercial launch readiness activities, including commercial site activation, provider and payer engagement, manufacturing activities and healthcare professional education, will not be successful or completed as planned; (viii) the risk that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (ix) the risk that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (x) the risk that estimated expenses will be higher than anticipated, cash, cash equivalents, and marketable securities will not provide operating runway into mid-2028 and the Company may not be able to obtain additional working capital with which to continue the clinical trials for NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed; (xi) the risk that the new hires will not contribute as expected including accelerating the planned path to commercialization; and (xii) those other risks disclosed in the section titled “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, as amended by that Form 10-K/A filed with the SEC on March 27, 2026, and other periodic or current reports subsequently filed with the SEC. These reports are available at www.sec.gov. Immix cautions that the foregoing list of important factors is not complete. Immix cautions readers not to place undue reliance on any forward-looking statements. Immix does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Company Contact
irteam@immixbio.com

IMMIX BIOPHARMA, INC.
SELECTED FINANCIAL DATA
(unaudited; in US$ millions, except share and per share data)

    Nine months ended
September 30, 2026
Three months ended
September 30, 2026
Statements of Cash Flows        
           
Cash flows provided by (used in) operating activities (33.9 ) (12.3 )
Cash flows provided by (used in) investing activities (14.2 ) (12.0 )
Cash flows provided by (used in) financing activities 274.4   119.2  
Effect of foreign currency on cash       —   —  
Increase (decrease) in cash and cash equivalents       226.4    94.8  
           
           
Statements of Operations and Comprehensive Loss    
Total operating expenses     (39.2 ) (15.9 )
of which Research and Development costs   (16.9 ) (5.5 )
of which General and Administrative costs   (22.3 ) (10.4 )
Operating loss     (39.2 ) (15.9 )
Financial gain (loss) – interest income   3.6   2.0  
Net loss before tax     (35.6 ) (13.9 )
Income tax       —   —  
Net loss for the period     (35.6 ) (13.9 )
           
Consolidated Balance Sheets   As of Jun 30, 2026 As of Sep 30, 2026
Cash, cash equivalents and marketable securities     234.1   340.9  
Non-current assets     3.3   3.3  
Other current assets     1.7   1.8  
Total Assets       239.1   346.0  
Total lease liabilities     1.0   1.0  
Accounts payable and accrued expenses   9.2   9.9  
Total Liabilities     10.2   10.9  
Total Stockholders’ Equity     228.9   335.1  
Total Liabilities and Stockholders’ Equity   239.1   346.0  
           

GREENVILLE, S.C., Nov. 12, 2026 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NYSE: UCB) (the “Company”) reported that its Board of Directors approved a quarterly cash dividend of $0.26 per share on the Company’s common stock. The dividend is payable on January 5, 2027, to shareholders of record as of December 15, 2026.

About United Community Banks, Inc.
United Community Banks, Inc. is the financial holding company for United Community Bank (“United Community”), a top-100 U.S. financial institution dedicated to building stronger communities and improving the financial health and well-being of its customers. United Community offers a full range of banking, mortgage, and wealth management services. As of September 30, 2026, United Community Banks, Inc. had $28.9 billion in assets and operated 202 offices across Alabama, Florida, Georgia, North Carolina, South Carolina, and Tennessee. It also manages a nationally recognized SBA lending franchise that extends its reach to businesses across the country.

United Community is the most awarded bank in the Southeast for Retail Banking Customer Satisfaction by J.D. Power, with recognition in 12 of the last 17 years, more than any other bank in the region. American Banker has named it one of the “Best Banks to Work For” for ten consecutive years. In commercial banking, it earned multiple 2026 Greenwich Best Bank awards for Small Business Banking, and Forbes has consistently ranked it among the World’s Best and America’s Best Banks.

Learn more at ucbi.com.

For more information:
Tom Speir
Chief Financial Officer
(864) 240-6208
Investor_Relations@ucbi.com

Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy combination expansion cohorts; on track for initial monotherapy data, including antitumor response for first-line non-small cell lung cancer (NSCLC) cohort in Q1 2027

Multiple Phase 2 studies of sacituzumab tirumotecan (sac-TMT) in combination with CR-001 ongoing in China led by partner, Kelun-Biotech, with initial data in NSCLC expected in mid-2027; additional antibody-drug conjugate (ADC) combinations planned; partnership achieved 9 IND clearances this year

First patient dosed in global Phase 1/2 APOLLO trial of CR-002, a PD-L1-targeted ADC

On track for multiple clinical data readouts in 2027 and more than 2,000 patients dosed across the portfolio by mid-year

WALTHAM, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced financial results for the third quarter ended September 30, 2026 and recent business highlights.

“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027. We plan to aggressively pursue additional combination opportunities that can further our efforts to develop CR-001 as a best-in-class IO backbone therapy. Building on the pipeline progress we outlined last month, we are pleased to have now commenced patient dosing in the global APOLLO trial of CR-002, our PD-L1-targeted ADC,” said Joshua Brumm, chief executive officer of Crescent. “The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types. We are poised for an exciting year ahead as we work to deliver the next wave of therapies for people living with cancer.”

Recent Business Highlights & Anticipated Milestones

CR-001, PD-1 x VEGF Bispecific Antibody

Clinical Execution Progress in ASCEND, a Global Phase 1/2 Trial of CR-001

  • In October 2026, Crescent announced completion of dose escalation in ASCEND, a global Phase 1/2 trial of CR-001, its investigational PD-1 x VEGF bispecific, with patients enrolled across several tumor types at clinical sites in the United States, Europe and South Korea.
  • Crescent is on track to report initial monotherapy data from ASCEND in the first quarter of 2027, including:
    • Preliminary antitumor response as measured by overall response rate (ORR) from a first-line NSCLC cohort of up to 12 patients.
    • Safety, tolerability, pharmacokinetic and pharmacodynamic data from more than 125 treatment-naïve and previously treated patients across multiple solid tumor types.
  • Patient dosing has commenced in ASCEND expansion cohorts which are evaluating CR-001 with various standard of care chemotherapy combinations across several solid tumor types in treatment-naive and previously treated patients, including first-line NSCLC, colorectal, biliary tract, gastric and endometrial cancers. Crescent is on track to report initial data from hundreds of patients in mid-2027 (Q2/Q3).
  • Data from the expansion cohorts, along with monotherapy data from ASCEND, will inform future clinical development for CR-001. Pending results and further interactions with regulators, Crescent plans to initiate the first of multiple Phase 3 trials of CR-001 in early 2028.
  • Trial in progress posters of the ASCEND study design were featured during the European Society for Medical Oncology (ESMO) 2026 Congress held October 23-27, 2026 in Madrid, Spain and at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting held November 4-8, 2026 in Phoenix, Arizona.

Multiple Studies Evaluating CR-001 in Combination with Novel ADCs

  • Under a collaboration agreement, Crescent granted Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., (“Kelun-Biotech”) exclusive rights to research, develop, and commercialize CR-001 (also known as SKB118) in Greater China. Both Kelun-Biotech and Crescent have rights to independently develop CR-001 in combinations, including with their respective antibody-drug conjugate (ADC) pipelines.
  • Kelun-Biotech is conducting multiple Phase 2 trials in China evaluating CR-001 (SKB118) in combination with sacituzumab tirumotecan (sac-TMT), its TROP2-directed ADC. Initial data from a study in patients with locally advanced or metastatic NSCLC are expected in mid-2027 (Q2/Q3). Additional studies are underway in participants with epidermal growth factor receptor (EGFR)-mutant locally advanced or metastatic non-squamous NSCLC who have failed EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, as well as in patients with advanced solid tumors.
  • A Phase 1/2 trial of CR-001 (SKB118) in combination with CR-003 (also known as SKB105), an integrin-beta 6 (ITGB6)-directed ADC, is expected to commence in the first half of 2027.

CR-002, Topoisomerase Inhibitor ADC Targeting PD-L1

  • Earlier this month, the first patient was dosed in the global Phase 1/2 APOLLO trial of CR-002, a topoisomerase inhibitor ADC targeting programmed cell death ligand 1 (PD-L1). APOLLO is designed to enroll patients in the United States, Europe and Asia Pacific with advanced solid tumors, including NSCLC, head and neck squamous cell carcinoma (HNSCC), and various gastrointestinal and gynecological tumors. The study’s dose escalation and tumor-specific backfill cohorts are expected to enroll approximately 200 participants with the opportunity for additional participants in expansion cohorts.
  • Crescent anticipates reporting initial data from APOLLO in the second half of 2027, including safety, tolerability, pharmacokinetics and preliminary antitumor activity.
  • Preclinical data for CR-002 will be featured in a poster presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held November 18-20, 2026 in Barcelona, Spain.

CR-003, Topoisomerase Inhibitor ADC Targeting ITGB6

  • Kelun-Biotech granted Crescent exclusive rights to research, develop, and commercialize CR-003 (SKB105), an ITGB6-targeted ADC, in the United States, Europe and all markets outside of Greater China.
  • A Phase 1/2 trial of CR-003 (SKB105) in participants with advanced solid tumors conducted by Kelun-Biotech in China is ongoing and proof-of-concept data are expected in the first quarter of 2027. Crescent plans to leverage data generated in China to support the global clinical development of CR-003 (SKB105).

Third Quarter 2026 Financial Results

Cash position: Cash and cash equivalents were $289.4 million as of September 30, 2026 which includes the $133.4 million in net proceeds from the July 2026 public offering. Crescent expects that its existing cash and cash equivalents will fund operations into the second half of 2028.

Research and development (R&D) expenses: R&D expenses were $34.3 million and $20.3 million for the three months ended September 30, 2026 and 2025, respectively. R&D expenses increased to support the increased clinical development on the global Phase 1/2 ASCEND trial and the costs incurred in preparation for the initiation on the global Phase 1/2 APOLLO trial.

General and administrative (G&A) expenses: G&A expenses were $8.7 million and $5.5 million for the three months ended September 30, 2026 and 2025, respectively. The increase in G&A expenses was primarily driven by increased personnel costs, including increased share-based compensation and professional service costs in continued support of the Company’s pipeline.

Net loss: Net loss was $37.7 million and $24.6 million, or $0.90 and $1.27 per basic and diluted share, for the three months ended September 30, 2026 and 2025, respectively.

Shares outstanding: As of September 30, 2026, Crescent had approximately 44.1 million ordinary shares and ordinary share equivalents issued and outstanding, including ordinary shares underlying pre-funded warrants and non-voting convertible preferred stock.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Crescent’s expectations, beliefs, or strategies regarding the future of its pipeline and business including, without limitation: the timing and success of clinical data from the ASCEND monotherapy and combination trials of CR-001; the potential initiation and success of Phase 3 studies of CR-001; the timing and success of the Phase 2 combination trials for CR-001 and sac-TMT, including the potential initiation of additional ADC combination studies by Kelun-Biotech; the trial design, indication selection, and timing and success of clinical data for the global Phase 1/2 APOLLO trial of CR-002; the timing and success of clinical data from the Phase 1/2 trial of CR-003 as generated by Kelun-Biotech in China; the expected benefits or opportunities with respect to CR-001, CR-002, and CR-003, including each product’s potential to act as a single agent or combination agent; the anticipated number of patients dosed across the portfolio; and Crescent’s anticipated cash runway. Forward-looking statements generally relate to future events or future financial or operating performance. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects and involve a number of risks, uncertainties or other assumptions that may cause actual performance to be materially different from those expressed or implied by these forward-looking statements. Risks and uncertainties include, but are not limited to: the expected benefits of, and opportunities related to, the strategic partnership between Crescent and Kelun-Biotech may not be realized or may take longer to realize than anticipated; Crescent’s limited operating history, including with respect to clinical trials; Crescent’s historical losses and any future ability to generate revenue; Crescent’s ability to raise capital to support its business plans; risks associated with clinical development and regulatory approval; risks related to Crescent’s intellectual property; Crescent’s reliance on third parties, including to help develop its product candidates, run its clinical trials, and manufacture its product candidates; significant disruptions of information technology systems or breaches of data security, litigation and regulatory risks; risks related to the current macroeconomic environment, including fluctuating interest rates, barriers to trade, changes to fiscal and monetary policy or government budget dynamics, geopolitical factors, including the ongoing conflicts in Iran and between Russia and Ukraine and the responses thereto, and supply chain disruptions, as well as those factors more fully described in Crescent’s most recent filings with the Securities and Exchange Commission (including its Quarterly Report on Form 10-Q), and Crescent’s other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Crescent’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Crescent does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements.

               
Crescent Biopharma, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(Unaudited)
               
  Three Months Ended September 30, 2026   Nine Months Ended September 30, 2026   Three Months Ended September 30, 2025   Nine Months Ended September 30, 2025
License agreement revenue $ 3,117     $ 4,156     $ —     $ —  
Operating expenses              
Research and development   34,305       71,598       20,347       43,059  
General and administrative   8,719       25,328       5,538       18,081  
Total operating expenses   43,024       96,926       25,885       61,140  
Other income   —       1,770       —       —  
Loss from operations   (39,907 )     (91,000 )     (25,885 )     (61,140 )
Other income (expense)   2,181       5,154       1,278       (405 )
Net loss and comprehensive loss $ (37,726 )   $ (85,846 )   $ (24,607 )   $ (61,545 )
               
Net loss per share attributable to ordinary shareholders, basic and diluted $ (0.90 )   $ (2.37 )   $ (1.27 )   $ (7.89 )
Net loss per share attributable to Series A non-voting convertible preferred shareholders, basic and diluted $ (899.31 )   $ (2,368.17 )   $ (1,266.44 )   $ (7,891.38 )
               
Weighted-average ordinary shares outstanding used in computing net loss per share to ordinary shareholders, basic and diluted   39,056,224       33,360,473       16,540,771       6,640,402  
Weighted-average Series A non-voting convertible preferred shares outstanding used in computing net loss per share to Series A non-voting convertible preferred shareholders, basic and diluted   2,890       2,890       2,890       1,160  
                               

Summary Balance Sheet Data
(in thousands)
(Unaudited)
           
  September 30, 2026
  December 31, 2025
Assets          
Cash $ 289,357     $ 213,192  
Other assets   10,146       27,101  
Total Assets $ 299,503     $ 240,293  
Liabilities and Shareholders’ Equity          
Liabilities $ 25,224     $ 37,281  
Shareholders’ equity   274,279       203,012  
Total liabilities and shareholders’ equity $ 299,503     $ 240,293  
               

Contacts

Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 5:40 a.m. ET / 10:40 a.m. GMT.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. Webcasts will also be archived for a minimum of thirty days.

About Royalty Pharma plc

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

Dallas, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) — Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced that members of the Enovis management team will be presenting at the Annual Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT (6:30 a.m. ET).

A link to the live audio webcast, as well as a replay of the event, will be available on the Company’s website under the Investors tab at Events and Presentations.

About Enovis 

Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Discover more about Enovis at www.enovis.com and follow us on Facebook, Instagram, LinkedIn and X.  

Investor Contact

Kyle Rose, Vice President, Investor Relations
investorrelations@enovis.com

Media Contact

Rachel Colloff, Sr. Director, Corporate Communications
Rachel.Colloff@enovis.com

Company advances strategic repositioning through substantial cost reductions and disciplined capital allocation, with resources focused on preserving and maximizing the value of its interest in Accelsius

ORLANDO, Fla., Nov. 12, 2026 (GLOBE NEWSWIRE) — ORLANDO, Fla., November 12, 2026 (GLOBAL NEWSWIRE) – Innventure, Inc. (NASDAQ: INV) (“Innventure”) today announced financial results for the quarter ended September 30, 2026.

“Over the last few months, our management team and Board have taken decisive steps to transform Innventure into a leaner, more focused organization, concentrating our resources on the opportunities we believe offer the clearest path to driving shareholder value,” said Bill Grieco, Chief Executive Officer of Innventure. “We have substantially reduced parent-level costs, including reducing headcount from 40 to 15 since the end of the first quarter, and we are transitioning AeroFlexx and Refinity away from reliance on Innventure capital while evaluating strategic alternatives for both businesses. At the same time, our Strategic Review Committee, together with our financial advisors, is evaluating capital strategies to strengthen our financial position and address our near-term liquidity needs in a disciplined manner. These actions share the common objective to preserve and maximize the value of our interest in Accelsius while giving the business the necessary resources to realize its full potential. We remain confident in the underlying opportunity at Accelsius and believe the transformation underway at Innventure is an important step toward translating that opportunity into value for our shareholders.”

Conference Call and Webcast

A conference call to discuss these results has been scheduled for 5:00 pm ET today, November 12, 2026.

The event will be webcasted live via our investor relations website https://www.innventure.com/investors or via https://innventure-3q26-earnings.open-exchange.net/.

About Innventure

Innventure (NASDAQ: INV) builds and scales the companies that it has founded as they commercialize new technologies. Innventure is focused on preserving and maximizing the value of its operating company interests for shareholders through disciplined capital allocation, focused execution, strong governance, and strategic initiatives. Learn more at innventure.com.

Non-GAAP Financial Measures

We use certain financial measures that are not calculated in accordance with generally accepted accounting principles in the U.S. (GAAP) to supplement our consolidated financial statements. These non-GAAP financial measures provide additional information to investors to facilitate comparisons of past and present operating results, identify trends in our underlying operating performance, and offer greater transparency on how we evaluate our business activities. These measures are integral to our processes for budgeting, managing operations, making strategic decisions, and evaluating our performance.

Our primary non-GAAP financial measures are EBITDA and Adjusted EBITDA. We define EBITDA as net income before interest, income taxes, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted to exclude certain non-cash items, non-recurring expenses, and other items that are not indicative of our core operating activities. These may include stock-based compensation, acquisition costs, and other financial items. We believe Adjusted EBITDA is valuable for investors and analysts as it provides additional insight into our operational performance, excluding the impacts of certain financing, investing, and other non-operational activities. This measure helps in comparing our current operating results with prior periods and with those of other companies in our industry. It is also used internally for allocating resources efficiently, assessing the economic outcomes of acquisitions and strategic decisions, and evaluating the performance of our management team.

There are limitations to Adjusted EBITDA, including its exclusion of cash expenditures, future requirements for capital expenditures and contractual commitments, and changes in or cash requirements for working capital needs. Adjusted EBITDA also omits significant interest expenses and related cash requirements for interest and payments. While depreciation and amortization are non-cash charges, the associated assets will often need to be replaced in the future, and Adjusted EBITDA does not reflect the cash required for such replacements. Additionally, Adjusted EBITDA does not account for income or other taxes or necessary cash tax payments.

Investors should use caution when comparing our non-GAAP measure to similar metrics used by other companies, as definitions can vary. Adjusted EBITDA should not be considered in isolation or as a substitute for GAAP financial measures.
In presenting Adjusted EBITDA, we aim to provide investors with an additional tool for assessing the operational performance of our business. It serves as a useful complement to our GAAP results, offering a more comprehensive understanding of our financial health and operational efficiencies.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release are “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are often identified by future or conditional words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “will,” “potential,” “predict,” “should,” “would” and other similar words and expressions (or the negative versions of such words or expressions), but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current assumptions and expectations of future events that are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of this press release. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the parties) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.

These risks and uncertainties include, but are not limited to, those factors described in Innventure’s public filings with the U.S. Securities and Exchange Commission, including, but not limited to, the following: Innventure’s and its subsidiaries’ ability to execute on their strategies, book sales and achieve future financial performance; Innventure’s ability to identify and execute on alternatives to strengthen its financial position; Innventure’s or each operating company’s respective ability to secure financing and/or other value-enhancing transactions, in each case as applicable, on acceptable terms or at all, including with respect to the dilution of Innventure’s interests in its operating companies; developments and projections relating to Innventure’s and its subsidiaries’ competitors and industry; the implementation, adoption, market acceptance and success of Innventure’s and its subsidiaries’ products, business models and growth strategies; Innventure’s and its subsidiaries’ ability to generate sufficient revenue and operating cash flow; the timing and magnitude of expected cash expenditures; the availability, timing and terms of additional financing, including debt or equity financing at Innventure or its subsidiaries; market conditions affecting access to capital; potential dilution resulting from future financings at Innventure or its subsidiaries; if additional funding is unavailable, or cannot be obtained on acceptable terms or in sufficient amounts or on a timely basis, AeroFlexx or Refinity may be required to wind up or cease operations; potential goodwill, intangible asset, and other asset impairment charges, write-offs of intercompany advances, and other costs and liabilities associated with any such wind-down or cessation of operations; the risk that one or both of AeroFlexx or Refinity may be unable to continue as a going concern if additional funding is not obtained; Innventure’s ability to successfully implement cost reduction initiatives; risks related to recent shareholder litigation; changes in economic conditions; competitive pressures; regulatory developments; and Innventure’s ability to maintain control over its subsidiaries.

The foregoing factors are not exhaustive. For a more complete discussion of the risks and uncertainties that may affect Innventure’s forward-looking statements, see the ‘Risk Factors’ section of Innventure’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. Forward‑looking statements speak only as of the date of this release, and Innventure undertakes no obligation to update them, whether as a result of new information, future events, changes in assumptions or expectations, or otherwise, except as required by applicable law or the rules of any stock exchange on which Innventure’s securities are listed.

Investor Relations Contact: Kyle Nagarkar, Solebury Strategic Communications
investorrelations@innventure.com 

Media Contact: Stephanie Knight, Solebury Strategic Communications
press@innventure.com 

       
Innventure, Inc. and Subsidiaries
Consolidated Balance Sheets
(in thousands, except share amounts)
       
  September 30, 2026   December 31, 2025
Assets      
Cash and cash equivalents $ 21,952     $ 60,449  
Restricted cash   5,000       5,000  
Accounts receivable   2,084       1,094  
Due from related parties   17,936       11,840  
Inventories   2,696       1,604  
Prepaid expenses and other current assets   3,513       3,167  
Total Current Assets   53,181       83,154  
Investments   25,460       28,741  
Property, plant and equipment, net   6,432       1,941  
Intangible assets, net   144,326       160,537  
Goodwill   —       323,463  
Other assets   1,312       1,351  
Total Assets $ 230,711     $ 599,187  
Liabilities and Stockholders’ Equity      
Accounts payable $ 4,382     $ 2,551  
Accrued employee benefits   3,735       11,343  
Accrued expenses   4,854       7,386  
Contract liabilities   410       947  
Notes payable – current   7,969       12,846  
Term convertible note, current   8,102       7,890  
Convertible promissory note, current   4,449       4,331  
Patent installment payable – current   825       700  
Obligation to issue equity   110       119  
Warrant liability   12,149       27,458  
Income taxes payable   32       23  
Related party convertible promissory notes-current   11       —  
Other current liabilities   395       682  
Total Current Liabilities   47,423       76,276  
Notes payable, net of current portion   4,405       8,327  
Earnout liability   490       3,890  
Stock-based compensation liability   —       239  
Patent installment payable, net of current   11,550       12,375  
Deferred income taxes   9,783       13,848  
Other liabilities   791       556  
Total Liabilities   74,442       115,511  
Commitments and Contingencies (Note 16)      
Stockholders’ Equity      
Preferred stock, $0.0001 par value, 25,000,000 shares authorized;      
Series B Preferred Stock, $0.0001 par value, 3,000,000 shares designated, 24,779 and 33,144 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively.   —       —  
Series C Preferred Stock, $0.0001 par value, 5,000,000 shares designated, 159,270 shares issued and outstanding as of September 30, 2026 and 150,000 shares issued and outstanding as of December 31, 2025.   —       —  
Common Stock, $0.0001 par value, 250,000,000 shares authorized, 86,556,511 and 67,743,847 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively.   8       7  
Additional paid-in capital   658,021       577,070  
Accumulated other comprehensive gain (loss)   (391 )     (1,260 )
Accumulated deficit   (621,283 )     (371,603 )
Total Innventure, Inc., Stockholders’ Equity   36,355       204,214  
Non-controlling interest   119,914       279,462  
Total Stockholders’ Equity   156,269       483,676  
Total Liabilities and Stockholder’s Equity $ 230,711     $ 599,187  

               
Innventure, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share amounts)
               
  Three Months Ended
September 30, 2026
  Three Months Ended
September 30, 2025
  Nine Months Ended
September 30, 2026
  Nine Months Ended
September 30, 2025
Revenue $ 1,481     $ 534     $ 3,877     $ 1,234  
               
Operating Expenses              
Cost of sales   5,175       4,147       15,501       7,192  
General and administrative   12,844       16,927       40,093       55,172  
Sales and marketing   1,875       2,514       7,861       6,818  
Research and development   9,502       6,151       27,122       18,472  
Goodwill impairment   323,463       —       323,463       346,557  
Total Operating Expenses   352,859       29,739       414,040       434,211  
               
Loss from Operations   (351,378 )     (29,205 )     (410,163 )     (432,977 )
               
Non-operating (Expense) and Income              
Interest expense, net   (934 )     (3,401 )     (2,454 )     (7,586 )
Net gain (loss) from investments   (49 )     —       59       —  
Change in fair value of financial liabilities   20,834       (4,109 )     18,709       19,496  
Equity method investment (loss) income   (1,489 )     (1,602 )     (4,496 )     (10,282 )
Realized gain on conversion of available for sale investment   —       —       —       1,507  
Loss on extinguishment of debt   —       —       (977 )     (3,462 )
Loss on extinguishment of related party debt   —       —       —       (3,538 )
Miscellaneous other expense   (284 )     (21 )     (1,232 )     (64 )
Total Non-operating Income (Expense)   18,078   —   (9,133 ) —   9,609       (3,929 )
Loss before Income Taxes   (333,300 )     (38,338 )     (400,554 )     (436,906 )
Income tax benefit   538       (3,603 )     (4,019 )     (7,222 )
Net Loss   (333,838 )     (34,735 )     (396,535 )     (429,684 )
Less: net loss attributable to              
Non-redeemable non-controlling interest   (131,466 )     (6,403 )     (146,855 )     (174,128 )
Net Loss Attributable to Innventure, Inc. Stockholders / Innventure LLC Unitholders   (202,372 ) —   (28,332 ) —   (249,680 )     (255,556 )
               
Basic and diluted loss per share $ (2.39 )   $ (0.51 )   $ (3.05 )   $ (4.96 )
Basic and diluted weighted average common shares   84,727,303       55,846,721       81,927,882       51,583,853  

       
Innventure, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(in thousands)
       
  Nine Months Ended September 30, 2026   Nine Months Ended September 30, 2025
Cash Flows Used in Operating Activities      
Net loss $ (396,535 )   $ (429,684 )
Adjustments to reconcile net loss to net cash used in operating activities:      
Stock-based compensation   15,615       22,972  
Interest income on debt securities – related party   (280 )     (299 )
Change in fair value of financial liabilities   (18,709 )     (19,496 )
Non-cash interest expense on notes payable   1,707       5,142  
Net gain on investments   (59 )     —  
Accrued unpaid interest on note payable   355       220  
Equity method investment loss (income)   4,496       10,282  
Realized gain on conversion of available for sale investments   —       (1,507 )
Loss on extinguishment of debt   977       3,462  
Loss on extinguishment of related party debt   —       3,538  
Deferred income taxes   (4,066 )     (8,141 )
Loss on Disposal of PPE   410       —  
Depreciation and amortization   16,934       16,821  
Goodwill impairment   323,463       346,557  
Other costs, net   1,409       233  
Changes in operating assets and liabilities:      
Accounts receivable   (990 )     (1,286 )
Prepaid expenses and other current assets   (6,442 )     (6,461 )
Inventory   (1,092 )     (1,226 )
Accounts payable   548       (2,448 )
Accrued employee benefits   (7,852 )     2,491  
Accrued expenses   (2,552 )     376  
Stock-based compensation liability   (227 )     (923 )
Income taxes payable   9       930  
Other current liabilities   (424 )     (230 )
Contract liabilities   (536 )     776  
Obligation to issue equity   —       2,158  
Other assets   16       (60 )
Patent installment payable   (700 )     (525 )
Net Cash Used in Operating Activities   (74,525 )     (56,328 )
       
Cash Flows (Used in) Provided by Investing Activities      
Investment in available-for-sale debt securities – equity method investee   —       (2,708 )
Acquisition of property, plant and equipment   (4,340 )     (1,371 )
Net Cash (Used in) Provided by Investing Activities   (4,340 )     (4,079 )
       
Cash Flows Provided by Financing Activities      
Proceeds from issuance of equity, net of issuance costs   51,819       3,675  
Proceeds from the issuance of equity to non-controlling interest, net of issuance costs   —       6,327  
Proceeds from the issuance of convertible promissory note   —       6,350  
Proceeds from the issuance of term convertible notes   —       14,950  
Proceeds from issuance of debt securities, net of issuance costs   —       36,000  
Payment of debts   (10,419 )     (3,877 )
Taxes paid related to net share settlement of equity awards   (1,032 )     —  
Distributions to Stockholders   —       (76 )
Cash Flows Provided by Financing Activities   40,368       63,349  
       
Net Decrease in Cash, Cash Equivalents and Restricted Cash   (38,497 ) —   2,942  
Cash, Cash Equivalents and Restricted Cash Beginning of period   65,449       11,119  
Cash, Cash Equivalents and Restricted Cash End of period $ 26,952     $ 14,061  

  Nine Months Ended September 30, 2026   Nine Months Ended September 30, 2025
Supplemental Cash Flow Information      
Cash paid for interest $ 1,646   $ 2,551
Supplemental Disclosure of Noncash Financing Information      
Conversion of working capital loans to equity method investee into investments in debt securities – related party   —     4,375
Unrealized gain on investments in debt Securities – related party through OCI   877     410
Extinguishment of debt with Series C Preferred Stock   —     14,000
Contribution of Series C Preferred Stock to equity method investee   —     5,783
Conversion of AFX available-for-sale term loan into equity method investments   —     8,757
Issuance of common stock as repayment of convertible debt   1,090     5,961
Issuance of vested RSUs   244     —
Issuance of stock in exchange for services   11     4,187
Equity reallocation between non-controlling interest and additional paid-in capital   20,766     36,313

               
Innventure, Inc. and Subsidiaries
Non-GAAP Financial Measures
(in thousands)
               
  Three Months Ended
September 30, 2026
  Three Months Ended
September 30, 2025
  Nine Months Ended
September 30, 2026
  Nine Months Ended
September 30, 2025
Net loss $ (333,838 )   $ (34,735 )   $ (396,535 )   (429,684 )
Interest expense, net(1)   934       3,401       2,454     7,586  
Depreciation and amortization expense   5,603       5,638       16,934     16,821  
Income tax expense (benefit)   538       (3,603 )     (4,019 )   (7,222 )
EBITDA   (326,763 )     (29,299 )     (381,166 )   (412,499 )
Change in fair value of financial liabilities(2)   (20,834 )     4,109       (18,709 )   (19,496 )
Stock-based compensation(3)   5,306       7,725       15,615     22,972  
Goodwill impairment(4)   323,463       —       323,463     346,557  
Loss on extinguishment of debt(5)   —       —       977     3,462  
Loss on extinguishment of related party debt(6)   —       —       —     3,538  
Adjusted EBITDA   (18,828 )     (17,465 )     (59,820 )   (55,466 )

(1) Interest Expense, net, includes interest incurred on our various borrowing facilities and the amortization of debt issuance costs.
(2) Change in fair value of financial liabilities – For the three and nine months ended September 30, 2026, and 2025, the change in fair value of financial liabilities primarily consists of the change in fair value of the warrant liability, the earnout liability and the embedded derivatives in various instruments.
(3) Stock based compensation – For the three and nine months ended September 30, 2026, and 2025, stock based compensation primarily consisted of awards in the 2024 Equity and Incentive Plan. These awards consisted of Stock Options, Restricted Stock Units, and Stock Appreciation Rights. Further, a portion of this expense was related to share-based payment employee incentive plans in existence at subsidiaries.
(4) Goodwill impairment – For the three and nine months ended June 30, 2025, the Company recognized goodwill impairment due to sustained decreases in the Company’s publicly quoted share price and market capitalization, which were, at least in part, sensitive to the general downward volatility experienced in the stock market in the comparable period in the prior year. There was no goodwill impairment for the three and nine months ended September 30, 2026.
(5) Loss on extinguishment of debt – For the nine months ended September 30, 2026, the Company repaid the Convertible Debentures, which resulted in an aggregate of $1.0 million loss on extinguishment of debt. There was no loss on extinguishment of debt for the three months ended September 30, 2026. For the three and nine months ended June 30, 2025, the Company recognized a loss on extinguishment of debt of $3.5 million in connection with the modification of the WTI Facility.
(6) Loss on extinguishment of related party debt – For the nine months ended June 30, 2025, the Company extinguished certain related party debts by issuing Series C Preferred Stock. There was no loss on extinguishment of related party debt for the three months ended September 30, 2026.

Residential revenue rebounds sequentially, supported by initial third-party ownership platform activity

Pendergrass manufacturing facility ramp on schedule

Utility-scale $116M Master Purchase Agreement for products built at the Georgia facility with deliveries anchoring the plant’s 2027 production ramp

SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV) (“NeoVolta” or the “Company”), a U.S.-based energy technology company delivering scalable energy storage solutions, today announced financial results for the quarter ended September 30, 2026.

Quarter Ended September 30, 2026 Financial Highlights

  • Revenue was $2.8 million, compared to approximately $13.5 thousand in the previous quarter ended June 30, 2026. The sequential recovery reflects initial sales of installed residential energy storage projects through the Company’s third-party ownership (“TPO”) platform.
  • Gross profit was $1.0 million, or 36.5% of revenue, compared to a gross loss of $1.1 million in the previous quarter ended June 30, 2026. The return to positive gross profit reflects the higher value of a fully installed project sales compared with a product-sale-only business model.
  • GAAP net loss was $7.7 million, or $(0.13) per share, compared to a net loss of $11.7 million, or $(0.24) per share in the previous quarter ended June 30, 2026.
  • Adjusted EBITDA was $(5.5) million, compared to $(8.0) million in the previous quarter ended June 30, 2026.
  • Cash and cash equivalents were $26.0 million as of September 30, 2026, plus $2.8 million of restricted cash, for total cash, restricted cash and cash equivalents of $28.8 million. This compares to $22.2 million in cash and cash equivalents and $3.2 million in restricted cash, for a total of $25.4 million as of June 30, 2026.
  • During the quarter, the Company closed a $20 million senior secured term loan to support working capital and general corporate purposes. The facility includes an additional uncommitted amount of up to $10 million, subject to lender agreement.

Business Highlights

During the quarter ended September 30, 2026, and subsequent to quarter-end, NeoVolta advanced its domestic manufacturing platform, expanded customer commitments and began generating revenue through its residential TPO platform.

  • Pendergrass production ramp underway. The Company is focused on production ramp-up at its Pendergrass, Georgia facility following its September opening.
  • Utility-scale pipeline conversion to backlog. The Company signed a $116M master purchase agreement for BESS products built at the Georgia facility, with deliveries anchoring the plant’s 2027 production ramp.
  • SK On strategic collaboration. During the quarter, NeoVolta Power announced its strategic supply and manufacturing collaboration with SK On, including a signed agreement for 9 GWh of U.S.-manufactured lithium iron phosphate (“LFP”) battery cells for delivery from 2027 through 2031. The collaboration supports the Company’s domestic supply chain strategy and the development of its U.S. manufacturing platform.
  • Initial commercial and industrial sales commitments. In October, NeoVolta launched commercial and industrial sales through an agreement providing for a minimum of $10 million in purchases through 2027. Multiple units are scheduled to ship during the fourth quarter of calendar 2026, establishing an initial commercial base as the Company expands this business.
  • Residential Third-Party Ownership (TPO) platform execution. The Company recognized $2.7 million in revenue from the first batch of residential energy storage projects through its TPO platform during the quarter. This revenue included estimated California Self-Generation Incentive Program rebates recognized as variable consideration. The TPO platform is intended to support further residential growth and expansion into commercial and industrial applications.

“Our focus is straightforward: execute the Pendergrass ramp, meet customer requirements and convert pipeline to committed backlog,” said Ardes Johnson, Chief Executive Officer of NeoVolta. “The backlog from utility-scale and C&I customers and residential recovery going into 2027 give us a more defined foundation for growth. Our pipeline remains robust, with continued interest in U.S.-made energy storage systems, and our priority is to deliver against the opportunities we have secured.”

“Our results for the quarter ended September 30, 2026 reflect initial execution of our residential TPO business model alongside continued investment in our manufacturing platform and operating capabilities,” said Jing Nealis, Chief Financial Officer of NeoVolta. “We ended the quarter with $28.8 million in cash, restricted cash and cash equivalents following the completion of our senior secured term loan financing. As we prepare for increased manufacturing activity, our capital allocation priorities remain focused on working capital, customer delivery requirements and disciplined investment aligned with our customers demand.”

Conference Call Information

NeoVolta will host a conference call and webcast on Thursday, November 12, 2026, at 5:00 p.m. Eastern Time to discuss its first quarter fiscal 2027 financial and operating results. Management will also discuss recent operational progress and strategic priorities, followed by a question-and-answer session.

  • Date: Thursday, November 12, 2026
  • Time: 5:00 pm ET
  • Dial-in: +1 (844) 825-9789
  • Webcast: Registration Link

A telephonic replay will be available from 9:00 p.m. Eastern Time on November 12, 2026, through Thursday, November 26, 2026. To access the replay, dial +1 (844) 512-2921 and enter replay PIN 10213108.

The webcast replay and accompanying presentation will be available on the Investor Relations section of the Company’s website at neovolta.com/investors.

About NeoVolta

NeoVolta is an innovator in energy storage solutions dedicated to advancing reliable, high-performance power infrastructure for residential, commercial, and utility applications. With a focus on scalable technology, domestic manufacturing, and strategic partnerships, NeoVolta is positioned to support the accelerating transition toward resilient energy systems.

For more information, visit www.neovolta.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the production ramp and commercial production at the Company’s Pendergrass, Georgia facility, the SK Battery America supply agreement and related pack collaboration, expected recovery in residential volumes, conversion of pipeline opportunities into binding orders, the Company’s manufacturing agreements and related potential purchase orders and delivery schedules, the Company’s commercial and industrial sales commitments, the Company’s senior secured term loan facility, and the Company’s growth plans and strategic priorities. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, and actual results may differ materially. Factors that could cause actual results to differ include, among others, risks related to the Company’s manufacturing ramp and facility commissioning, joint venture execution, customer order conversion, residential market conditions, changes in federal tax policy or IRA incentive programs, supply arrangements including the SK Battery America collaboration, availability and terms of additional financing, and access to capital, as well as other factors described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

Non-GAAP Financial Measures

To supplement our financial results presented on a basis in conformity with generally accepted accounting principles in the United States (“GAAP”), we use the non-GAAP measure: Adjusted EBITDA which excludes from our GAAP net loss, interest, taxes, depreciation and amortization, as well as other significant expenses including stock-based compensation that we believe are helpful in understanding our past financial performance. Our non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

Management believes that these non-GAAP financial measures reflect our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in its business, as they exclude expenses and gains not reflective of ongoing operating results or that may be infrequent and/or unusual in nature. We exclude the nonoperating credit loss expenses as these costs were non-operational in nature and they are not indicative of our ongoing operational results. We also adjust for the effect of stock-based compensation expenses noting that such expenses will recur in future periods. Although stock-based compensation is a key incentive offered to our employees, we continue to evaluate our business performance internally excluding stock-based compensation expenses.

Management also believes that these non-GAAP financial measures provide useful information to investors in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. These non-GAAP measures may not be comparable to similarly titled measures presented by other companies. In this press release, we have provided a reconciliation of non-GAAP Adjusted EBITDA to GAAP net loss, the most directly comparable GAAP financial measure, in the tables that follow.

Contacts

NEOV Investors
Bryan Baritot
Alliance Advisors IR
ir@neovolta.com  

NEOV Media
Email: press@neovolta.com
Phone: 800-364-5464

                 
NEOVOLTA, INC.
Consolidated Balance Sheets
(Unaudited)
 
                 
    September 30,     June 30,  
    2026     2026  
Assets                
Current assets:                
Cash and cash equivalents   $ 25,966,018     $ 22,201,975  
Restricted cash     1,901,700       3,150,000  
Accounts receivable, net     3,342,024       2,945,468  
Inventory, net     5,907,840       2,133,153  
Prepaid expenses (including prepaid inventory in amounts of $1,357,736 and $931,685, respectively)     4,259,130       2,145,487  
Contract assets     1,664,141       –  
Other current assets     352,292       272,280  
Total current assets     43,393,145       32,848,363  
                 
Construction in progress     9,848,182       9,602,302  
Leasehold improvements, net     6,432,986       –  
Other property and equipment     1,716,810       323,804  
Net property and equipment     17,997,978       9,926,106  
                 
Intellectual property (net of accumulated amortization of $452,910)     945,590       1,064,641  
                 
Other assets:                
Lease right-of-use assets, net     7,882,951       8,082,546  
Prepaid service fee under third party platform     2,847,222       1,631,944  
Restricted cash and other noncurrent assets     1,038,787       84,347  
                 
Total assets   $ 74,105,673     $ 53,637,947  
                 
Liabilities and Stockholders’ Equity                
Current liabilities:                
Accounts payable – other   $ 8,090,653     $ 3,590,368  
Accounts payable – related party     233,910       233,910  
Accrued liabilities     5,307,857       1,038,936  
Lease liabilities     735,916       695,269  
Short-term debt payable     15,073,584       1,120,000  
Derivative liability     278,362       –  
Total current liabilities     29,720,282       6,678,483  
Long-term debt payable     –       –  
Lease liabilities     7,208,943       7,392,124  
Total liabilities     36,929,225       14,070,607  
                 
Commitments and contingencies (Note 7)                
                 
Stockholders’ equity:                
Common stock, $0.001 par value, 100,000,000 shares authorized, 59,013,247 shares and 58,308,247 shares issued and outstanding, respectively     59,013       58,308  
Additional paid-in capital     92,098,438       86,756,877  
Accumulated deficit     (54,981,003 )     (47,247,845 )
Total stockholders’ equity     37,176,448       39,567,340  
                 
Total liabilities and stockholders’ equity   $ 74,105,673     $ 53,637,947  

             
NEOVOLTA, INC.
Consolidated Statements of Operations
(Unaudited)
 
             
    Three Months Ended  
    September 30,  
    2026     2025  
             
Revenues from contracts with customers:   $ 2,786,782     $ 6,650,258  
Cost of revenues     1,768,895       5,073,006  
Gross profit     1,017,887       1,577,252  
                 
Operating expenses:                
General and administrative     7,336,224       2,374,668  
Research and development     766,928       56,912  
Depreciation and amortization     231,856       –  
Total operating expenses     8,335,008       2,431,580  
                 
Loss from operations     (7,317,121 )     (854,328 )
                 
Other income (expense):                
Interest expense     (521,310 )     (389,134 )
Nonoperating credit loss and other     (28,955 )     –  
Interest income     134,228       140  
Total other income (expense)     (416,037 )     (388,994 )
                 
Net loss   $ (7,733,158 )   $ (1,243,322 )
                 
Weighted average shares outstanding – basic and diluted     58,950,149       34,193,531  
                 
Net loss per share – basic and diluted   $ (0.13 )   $ (0.04 )

                 
NEOVOLTA, INC.
Consolidated Statements of Cash Flows
(Unaudited)
 
                 
    Three Months Ended  
    September 30,  
    2026     2025  
Cash flows from operating activities:                
Net loss   $ (7,733,158 )   $ (1,243,322 )
Adjustments to reconcile net loss to net cash used in operations:                
Stock compensation expense     1,570,837       466,765  
Amortization of debt discount     369,200       –  
Amortization of ROU asset     199,595       50,965  
Depreciation and amortization expense     231,856       –  
Provision for expected credit losses/bad debt expense     72,232       135,800  
Inventory obsolescence reserve     20,293       –  
Loss on derivative     6,467       –  
Changes in other assets and liabilities                
Accounts receivable     (468,788 )     (2,362,338 )
Inventory     (3,794,980 )     977,697  
Prepaid expenses     (3,328,921 )     (410,074 )
Contract assets     (1,664,141 )     –  
Other current assets     (166,628 )     –  
Accounts payable     4,063,102       (491,715 )
Other asset     (43,042 )     –  
Accrued liabilities     4,191,196       433,118  
Lease liability     (142,534 )     (50,965 )
Net cash flows used in operating activities     (6,617,414 )     (2,494,069 )
                 
Cash flows from investing activities:                
Additions to construction in progress     (6,798,661 )     –  
Additions to other property & equipment     (551,157 )     –  
Net cash flows used in investing activities     (7,349,818 )     –  
                 
Cash flows from financing activities:                
Borrowing under secured debt facility (including allocated value of imbedded common stock warrants and derivatives)     18,648,275       –  
Borrowings under line of credit     –       250,000  
Borrowings under short-term notes payable     –       4,199,549  
Repayments of short-term notes payable     (1,120,000 )     (2,660,497 )
Payment of debt financing costs     (133,900 )     –  
Advance received for stock subscription     –       800,000  
Net cash flows provided by financing activities     17,394,375       2,589,052  
                 
Net increase in cash and restricted cash     3,427,143       94,983  
Cash, restricted cash and cash equivalents at beginning of period     25,351,975       794,836  
Cash, restricted cash and cash equivalents at end of period   $ 28,779,118     $ 889,819  
                 
Supplemental disclosures of cash flow information                
Cash paid for interest   $ 13,005     $ 290,856  
Cash paid for income taxes     –       –  
                 
Supplemental disclosures of financing and investing activities                
Transfers from construction in progress to other property and equipment   $ 7,387,639     $ –  
Warrant issued for debt discount     3,492,781       –  
Derivative liability recognized on debt issuance     275,149       –  
Other equity contribution for services     319,950       –  
Deferred debt issuance costs allocated to note and warrant     217,262       –  

                         
NEOVOLTA, INC.
GAAP to Non-GAAP Reconciliation of Net Loss to Adjusted EBITDA
(Unaudited)
 
                         
    Three Months Ended  
    September 30,     June 30,  
    2026     2025     2026  
                         
Net loss   $ (7,733,158 )   $ (1,243,322 )   $ (11,660,188 )
Interest expense     521,310       389,134       22,097  
Interest income     (134,228 )     (140 )     (80,125 )
Depreciation and amortization     231,856       –       136,537  
Share-based compensation     1,570,837       466,765       2,150,677  
Loss on debt exchanges     –       –       –  
Nonoperating credit loss and other     28,955       –       1,430,837  
Adjusted EBITDA   $ (5,514,427 )   $ (387,563 )   $ (8,000,164 )

Elgin, IL, Nov. 12, 2026 (GLOBE NEWSWIRE) —

John B. Sanfilippo & Son, Inc. Announces Share Repurchase Program and Special Dividend

Elgin, IL, November 12, 2026 — John B. Sanfilippo & Son, Inc. (NASDAQ: JBSS) (the “Company”) today announced that its Board of Directors (the “Board”) has authorized a share repurchase program of up to $20 million of the Company’s Common Stock (the “Repurchase Program”) and has declared a special cash dividend (the “Special Dividend”) of $2.00 per share on all issued and outstanding shares of Common Stock and Class A Common Stock.

“Our strong balance sheet and consistent cash generation provide us with the flexibility to both invest in the future of the business and return capital to stockholders,” said Jasper Sanfilippo, Jr., Chief Executive Officer. “We remain confident in our long-term growth strategy and the opportunities we see across our portfolio. The Repurchase Program and Special Dividend reflect our commitment to balanced and disciplined capital allocation, while reinforcing our goal of creating long-term stockholder value through the responsible use of cash. We believe our stock represents an attractive long-term investment, and we believe the Repurchase Program provides an effective means of returning capital to our stockholders while preserving our ability to pursue growth opportunities.”

The Repurchase Program permits the Company to repurchase up to $20.0 million of its Common Stock from time to time through open-market purchases, through privately negotiated transactions, or other approved methods in accordance with applicable federal securities laws. The Repurchase Program does not obligate the Company to purchase any shares of its Common Stock and will remain in effect for two years unless modified, suspended, or terminated by the Company’s Board of Directors. The timing and actual number of shares repurchased will depend on a variety of factors, including market conditions and other considerations. The Repurchase Program does not authorize the repurchase of shares of Class A Common Stock.

In addition to authorizing the Repurchase Program, the Board also declared a Special Dividend of $2.00 per share on all issued and outstanding shares of Common Stock and Class A Common Stock. The Special Dividend will return approximately $24.0 million to stockholders. The Special Dividend will be paid on December 18, 2026, to stockholders of record as of the close of business on December 4, 2026.

Frank Pellegrino, President and Chief Financial Officer, added, “today’s announcement demonstrates the strength of our financial position and our commitment to disciplined capital allocation. We are pleased to return significant capital to our stockholders while preserving the flexibility to invest in the business and pursue future growth opportunities. Our capital allocation priorities remain unchanged: investing in the business to support long-term growth, maintaining a strong balance sheet, pursuing strategic opportunities, and returning capital to stockholders. This balanced approach enables us to create value for stockholders today while positioning the Company for continued long-term success.”

Upcoming Event
The Company will be presenting at the Southwest IDEAS conference in Dallas, Texas on November 18, 2026. Qualified investors that would like to schedule a meeting with management should contact Three Part Advisors at 817-310-8776.

Forward Looking Statements
Some of the statements in this release are forward-looking. These forward-looking statements may be generally identified by the use of forward-looking words and phrases such as “will”, “intends”, “may”, “believes”, “anticipates”, “should” and “expects” and are based on the Company’s current expectations or beliefs concerning future events and involve risks and uncertainties. Consequently, the Company’s actual results could differ materially. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events or other factors that affect the subject of these statements, except where expressly required to do so by law. Among the factors that could cause results to differ materially from current expectations are: (i) sales activity for the Company’s products, such as a decline in sales to one or more key customers, or to customers or in the nut and bars categories generally, in some or all channels, a change in product mix to lower price products, a decline in sales of private brand products or changing consumer preferences, including a shift from higher margin products to lower margin products; (ii) changes in the availability and costs of raw materials and ingredients due to global conflict, tariffs and other import restrictions and the impact of fixed price commitments with customers; (iii) the ability to pass on price increases to customers if commodity costs rise and the potential for a negative impact on demand for, and sales of, our products from price increases; (iv) the ability to measure and estimate bulk inventory, fluctuations in the value and quantity of the Company’s nut inventories due to fluctuations in the market prices of nuts and bulk inventory estimation adjustments, respectively; (v) the Company’s ability to appropriately respond to, or lessen the negative impact of, competitive and pricing pressures; (vi) losses associated with product recalls, product contamination, food labeling or other food safety issues, or the potential for lost sales or product liability if customers lose confidence in the safety of the Company’s products or in nuts or nut products in general, or are harmed as a result of using the Company’s products; (vii) the ability of the Company to control costs (including inflationary costs) and manage shortages or other disruptions in areas such as inputs, transportation and labor; (viii) uncertainty in economic conditions, including the potential for inflation or economic downturn leading to decreased consumer demand; (ix) the timing and occurrence (or nonoccurrence) of other transactions and events which may be subject to circumstances beyond the Company’s control; (x) the adverse effect of labor unrest or disputes, litigation and/or legal settlements, including potential unfavorable outcomes exceeding any amounts accrued; (xi) losses due to significant disruptions at any of our production or processing facilities, our inability to meet or fulfill customer orders on a timely basis, if at all, or employee unavailability due to labor shortages; (xii) the ability to implement our Long-Range Plan, including growing our branded and private brand product sales, diversifying our product offerings (including by the launch of new products) and expanding into alternative sales channels; (xiii) technology disruptions or failures or the occurrence of cybersecurity incidents or breaches; (xiv) the inability to protect the Company’s brand value, intellectual property or avoid intellectual property disputes; and (xv) our ability to manage the impacts of changing weather patterns on raw material availability due to climate change.

CONTACT: Frank Pellegrino
Chief Financial Officer
847-214-4138

Investor Relations Contact:
John Beisler or Steven Hooser
Three Part Advisors, LLC
817-310-8776

RALEIGH, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) — The board of directors of Martin Marietta Materials, Inc. (NYSE: MLM) (“Martin Marietta” or the “Company”) today declared a regular quarterly cash dividend of $0.84 per share on the Company’s outstanding common stock. This dividend will be payable on December 31, 2026, to shareholders of record at the close of business on December 1, 2026.

Martin Marietta, a member of the S&P 500 Index, is an American-based company and a leading supplier of aggregates, lime and limestone products, magnesia-based products and other building materials. Supported by industry-leading reserves and a network of operations across the United States, Canada and the Caribbean, Martin Marietta supplies the essential materials that help build, connect and sustain communities across North America. For more information, visit www.martinmarietta.com or www.magnesiaspecialties.com.

Investor Contact:
Jacklyn Rooker
Vice President, Investor Relations
(919) 510-4736
Jacklyn.Rooker@martinmarietta.com

MLM-D

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.